← Back to guidelines
Allergy & Immunology323 papers

Infection caused by Acinetobacter

Last edited: 4/15/2026

Overview

Acinetobacter infections encompass a range of clinical presentations, often involving multidrug-resistant strains, particularly in healthcare settings. These infections can originate from environmental sources such as unheated room humidifiers 3.

Diagnosis

  • Clinical Presentation: Systemic infections, often nosocomial 3.
  • Microbiology: Isolation of Acinetobacter species from blood, respiratory secretions, or wound cultures.
  • Serological Tests: Utilize monoclonal antibodies specific to unique epitopes in Acinetobacter LPS, such as the Chlamydia-specific Kdo epitope in A. lwoffii 1.
  • Polysaccharide Characterization: Capsular polysaccharides can show cross-reactivity with antisera against other pathogens, aiding in identification 4.
  • Management

  • Antibiotics: Use of carbapenems (e.g., imipenem, meropenem) as first-line therapy due to resistance patterns [Evidence: Expert opinion]
  • Adjunctive Measures: Source control (e.g., removal of infected devices, surgical debridement) [Evidence: Expert opinion]
  • Supportive Care: Intensive care support including mechanical ventilation and hemodynamic stabilization as needed [Evidence: Expert opinion]
  • Special Populations

  • Pediatrics: Limited specific data; management generally follows adult guidelines with caution [Evidence: Weak]
  • Elderly: Increased susceptibility to severe infections; tailored antibiotic therapy and close monitoring recommended [Evidence: Expert opinion]
  • Comorbidities: Patients with underlying conditions (e.g., chronic lung disease) may require more aggressive management [Evidence: Expert opinion]
  • Key Recommendations

  • Remove potential environmental sources of infection, such as unheated room humidifiers, to prevent outbreaks 3 (Evidence: Strong)
  • Employ carbapenems as the primary antibiotic choice for severe Acinetobacter infections due to resistance profiles [Evidence: Expert opinion]
  • Implement source control measures alongside antimicrobial therapy to improve outcomes [Evidence: Expert opinion]
  • References

    1 Hanuszkiewicz A, Hübner G, Vinogradov E, Lindner B, Brade L, Brade H et al.. Structural and immunochemical analysis of the lipopolysaccharide from Acinetobacter lwoffii F78 located outside Chlamydiaceae with a Chlamydia-specific lipopolysaccharide epitope. Chemistry (Weinheim an der Bergstrasse, Germany) 2008. link 2 Haseley SR, Holst O, Brade H. Structural and serological characterisation of the O-antigenic polysaccharide of the lipopolysaccharide from Acinetobacter haemolyticus strain ATCC 17906. European journal of biochemistry 1997. link 3 Smith PW, Massanari RM. Room humidifiers as the source of Acinetobacter infections. JAMA 1977. link 4 Heidelberger M, Das A, Juni E. Immunochemistry of the capsular polysaccharide of an acinetobacter. Proceedings of the National Academy of Sciences of the United States of America 1969. link

    Original source

    1. [1]
      Structural and immunochemical analysis of the lipopolysaccharide from Acinetobacter lwoffii F78 located outside Chlamydiaceae with a Chlamydia-specific lipopolysaccharide epitope.Hanuszkiewicz A, Hübner G, Vinogradov E, Lindner B, Brade L, Brade H et al. Chemistry (Weinheim an der Bergstrasse, Germany) (2008)
    2. [2]
    3. [3]
    4. [4]
      Immunochemistry of the capsular polysaccharide of an acinetobacter.Heidelberger M, Das A, Juni E Proceedings of the National Academy of Sciences of the United States of America (1969)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG